{"id":"NCT02264990","sponsor":"AbbVie","briefTitle":"Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers","officialTitle":"A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-30","primaryCompletion":"2019-11-14","completion":"2020-02-21","firstPosted":"2014-10-15","resultsPosted":"2021-02-26","lastUpdate":"2021-02-26"},"enrollment":595,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-squamous Non-small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Veliparib","otherNames":["ABT-888"]},{"type":"DRUG","name":"Pemetrexed","otherNames":["Alimta"]}],"arms":[{"label":"Veliparib + Carboplatin + Paclitaxel","type":"EXPERIMENTAL"},{"label":"Investigator's Choice Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.","primaryOutcome":{"measure":"Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup","timeFrame":"From randomization up to the data cut-off date of 15 July 2019; median follow-up time was 44.5 and 45.3 months in LSP+ participants for the investigator's choice chemotherapy and veliparib + C/P arms, respectively.","effectByArm":[{"arm":"Investigator's Choice Chemotherapy","deltaMin":9.2,"sd":null},{"arm":"Veliparib + Carboplatin + Paclitaxel","deltaMin":11.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.113"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":140,"countries":["United States","Argentina","Australia","Canada","Czechia","Denmark","Finland","Germany","Hungary","Israel","Japan","Netherlands","New Zealand","Russia","South Africa","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["35331641"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":98,"n":288},"commonTop":["ANAEMIA","NAUSEA","NEUTROPENIA","PERIPHERAL SENSORY NEUROPATHY","ALOPECIA"]}}